HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by MacKinnon, M. Articles by Jeffrey, R. R. Search for Related Content PubMed PubMed Citation Articles by MacKinnon, M. Articles by Jeffrey, R. R.

European Journal of Cardio-Thoracic Surgery, Vol 11, 838-842, Copyright © 1997 by European Association for Cardio-thoracic Surgery

ARTICLES

p53, c-erbB-2 and nm23 expression have no prognostic significance in primary pulmonary adenocarcinoma

M MacKinnon, KM Kerr, G King, MM Kennedy, JS Cockburn and RR Jeffrey
Department of Pathology, Aberdeen Royal Infirmary, Foresterhill, UK.

OBJECTIVE: We analysed nm23, c-erbB-2 and p53 protein expression in lung adenocarcinoma in relation to clinicopathological status and patient survival, to elucidate any potential prognostic value. Published reports suggest that high p53 and c-erbB-2 protein expression and loss of nm23 protein expression are associated with poor prognosis. METHODS: A total of 162 pulmonary adenocarcinomas resected between 1980 and 1991 were stained using monoclonal antibodies to nm23 (NCL-nm23), c- erbB-2 (NCL-CB11) and p53 (DAKO Do7). Antigen retrieval was by microwave heating and bound antibody was visualised using standard immunohistochemical methods. Staining was scored by two observers blinded to tumour status and patient survival. RESULTS: Of the tumours, 101/162 (62.3%) exhibited high-level p53 expression, 30 (18.5%) showed high-level c-erbB-2 membrane staining, and 77 (47.5%) demonstrated loss of nm23 positivity. The influence of T and N status and disease stage on postoperative survival was as expected. The predicted effect on patient survival of nm23, c-erbB-2 or nm23 protein expression suggested by previous studies was not verified by our work. This was true both overall and for groups within the same T or N status or stage. CONCLUSION: Immunohistochemical assessment of the nm23, c-erbB-2 and p53 proteins using the above monoclonal antibodies does not have value as an independent prognostic indicator in pulmonary adenocarcinoma.

This article has been cited by other articles:

				A N J Graham, P Maxwell, K Mulholland, A H Patterson, N Anderson, K G McManus, H Bharucha, and J A McGuigan Increased nm23 immunoreactivity is associated with selective inhibition of systemic tumour cell dissemination J. Clin. Pathol., March 1, 2002; 55(3): 184 - 189. [Abstract] [Full Text] [PDF]

				E. Steels, M. Paesmans, T. Berghmans, F. Branle, F. Lemaitre, C. Mascaux, A.P. Meert, F. Vallot, J.J. Lafitte, and J.P. Sculier Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis Eur. Respir. J., October 1, 2001; 18(4): 705 - 719. [Abstract] [Full Text] [PDF]

				C. Zafon, G. Obiols, J. CastellvI, N. Tallada, P. Galofre, E. Gemar, J. Mesa, and R. Simo nm23-H1 Immunoreactivity as a Prognostic Factor in Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3975 - 3980. [Abstract] [Full Text] [PDF]

				T. Mitsudomi, N. Hamajima, M. Ogawa, and T. Takahashi Prognostic Significance of p53 Alterations in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis Clin. Cancer Res., October 1, 2000; 6(10): 4055 - 4063. [Abstract] [Full Text]